Nurexone's Six-Month Clock: Can a Letter of Intent Keep the Rally Alive?

Nurexone's shares surge 42% on partnership and preclinical data, but the six-month LOI deadline with Made Scientific could end the rally if no definitive agreement is signed.

The rally in Nurexone Biologic's stock has been nothing short of dramatic — but the company now faces a deadline that will determine whether the momentum is sustainable or merely speculative froth.

Shares slipped 3.4 percent to EUR 0.4020 in the latest session, a modest pullback that does little to erase the broader picture: a 42 percent gain over the past week and 30 percent over the past month, fueled by a cluster of positive corporate announcements. The most significant of these arrived in mid-August 2026, when Nurexone and its U.S. subsidiary Exo-Top signed a binding letter of intent with Made Scientific to establish a manufacturing partnership.

Here's the catch: the agreement is a framework, not a final contract. If the two parties fail to convert it into a definitive agreement within six months of signing, the arrangement — including all exclusivity rights — expires automatically. That ticking clock now hangs over the share price.

The Bull Case: Two Engines Running in Tandem

Optimists point to a dual-track story. On the manufacturing side, Made Scientific is positioned to serve as Nurexone's exclusive U.S. partner for production and aseptic filling of bone marrow-derived exosomes, with first GMP batches targeted for the first half of 2027. The proposed definitive contract would carry an initial five-year term with renewal options.

On the science side, Nurexone recently published preclinical tissue data reinforcing the neuroprotective potential of ExoPTEN in spinal cord injury models. Two months after injury, treated animals showed significantly more cells containing myelin basic protein — a key component of the insulating layer around nerve fibers — compared with controls. The combination of industrial progress and scientific validation has powered the recent surge and could attract further speculative interest if more news follows.

Notably, the company also terminated a non-binding letter of intent with BioXtek, signed in April, as part of a strategic decision to consolidate U.S. GMP manufacturing under the Made Scientific umbrella. Nurexone leaves the door open for potential collaborations with BioXtek outside direct production, but the message is clear: a company of this size cannot sustain competing manufacturing tracks. Consolidation over diversification — rarely the flashier narrative, often the wiser one.

The Bear Case: Intent Is Not Delivery

Skeptics have equally concrete concerns. The Made Scientific agreement remains a letter of intent, not a signed supply contract. Nothing guarantees both sides will convert the framework into a binding agreement, and letting the six-month window lapse would remove one of the rally's key pillars.

ExoPTEN, meanwhile, remains in preclinical development. Nurexone plans to file an IND application in 2026 to move the program into clinical trials, but that filing has not yet been submitted. The recent tissue data, while scientifically supportive, constitutes animal-model evidence — not proof of efficacy in humans.

Technical indicators add another layer of caution. The relative strength index sits at 71.2, signaling overbought conditions. The stock trades 25 percent above its 50-day moving average of EUR 0.3218, a gap that often precedes normalization after a rapid run — regardless of fundamental news flow.

What Happens Next

The path forward hinges on two concrete milestones: converting the Made Scientific letter of intent into a final manufacturing agreement, and filing the IND application for ExoPTEN. Achieving either would substantially strengthen the bull thesis. Delays or a lapse of the six-month deadline would validate the bear case and likely accelerate the technical correction the overbought RSI already hints at.

Even after the recent sprint, the stock sits 42 percent below its 52-week high of EUR 0.6880, reached on September 24 last year — a reminder that the rally has only recovered a portion of prior losses. Should profit-taking unwind the overbought condition, a pullback to the 200-day moving average at EUR 0.3846 is plausible, even absent negative fundamental news. The stock's extreme annualized volatility of 93 percent makes such a scenario all the more likely.

One additional factor deserves attention: Nurexone recently engaged BullVestor for investor relations services, which may partly explain the stock's rising visibility. For investors familiar with early-stage clinical biotech, the dynamic is a familiar one — price action often runs far ahead of hard milestones. The science looks promising, but the operative question is whether Nurexone can convert a letter of intent into a durable, multi-year manufacturing contract before the current attention fades.